title: Effect of recombinant human erythropoietin treatment in uremic patients on oxygen affinity of hemoglobin.
abstract: Anemia of chronic renal failure is associated with a reduced affinity of hemoglobin for oxygen (Hb-O2 affinity). It has been reported that the correction of renal anemia by recombinant human erythropoietin (rhuEPO) treatment could be associated paradoxically with a further decrease in Hb-O2 affinity. We investigated changes in the compensatory mechanisms of chronic renal anemia during 25 weeks of rhuEPO treatment, in 19 chronic hemodialyzed (HD) patients. There was no significant variation of mean standard P50 (P50std). Average 2,3-diphosphoglycerate (DPG) increased after 13 weeks and remained stable. The large interindividual variations prompted us to study delta P50std and delta Hb. We demonstrated a negative correlation between delta P50std and delta Hb. Thus, P50std increased in patients who did not immediately correct their anemia and decreased in patients whose Hb values rose. These data showed that the major factor influencing variations of Hb-O2 affinity in chronic HD patients treated by rhuEPO is the variation of Hb concentrations. In our study, it was demonstrated that the most important rise in P50std and 2,3-DPG occurred in patients who were late responders to rhuEPO.
authors.affiliation: Service de Néphrologie, Hôpital Sainte Marguerite, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Brunet
authors.forename: Y
authors.initials: Y
authors.lastname: Berland
authors.forename: T
authors.initials: T
authors.lastname: Merzouk
authors.forename: D
authors.initials: D
authors.lastname: Vanuxem
authors.forename: M
authors.initials: M
authors.lastname: Badier
authors.forename: H
authors.initials: H
authors.lastname: Klinkmann
authors.forename: A
authors.initials: A
authors.lastname: Crevat
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007676:Kidney Failure, Chronic / Q000097:blood; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014511:Uremia / Q000097:blood* / Q000188:drug therapy*
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D010100:Oxygen